Nxera Pharma: Daridorexant Phase 3 Trial in South Korea Meets Primary and Secondary Endpoints for Insomnia

Nxera Pharma announced that its Phase 3 clinical trial of daridorexant in South Korea met both primary and secondary endpoints for the treatment of insomnia, with results reported on January 19, 2026. The trial demonstrated statistically significant improvements in sleep onset latency and total sleep time compared to placebo. The study included 450 adult patients with moderate-to-severe insomnia. Key outcomes showed a 35% reduction in sleep onset latency (p < 0.001) and a 42-minute increase in total sleep time (p = 0.002). Adverse events were mild and similar across treatment and placebo groups. Nxera plans to submit data to regulatory authorities in South Korea and the U.S. later this year. The company’s shares rose 8.7% in pre-market trading following the announcement.